

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC.,
Petitioner

v.

CORCEPT THERAPEUTICS, INC.,
Patent Owner

Case PGR2019-00048
U.S. Patent No. 10,195,214

DECLARATION OF LAURENCE KATZNELSON, M.D.

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	EXPERIENCE AND QUALIFICATIONS.....	2
III.	SUMMARY OF OPINIONS.....	4
IV.	BACKGROUND	5
	A. Cushing’s Syndrome	5
	B. Korlym®	6
	C. Drug-Drug Interactions	8
	D. My Practices for Treatment of Cushing’s Syndrome.....	10
V.	LEGAL STANDARDS	11
VI.	THE ’214 PATENT CLAIMS WOULD NOT HAVE BEEN OBVIOUS...12	
	A. The POSA.....	13
	B. Dr. Greenblatt’s Cited References	15
	1. The 2012 Korlym® Label	15
	2. Lee.....	19
	3. FDA Guidance	22
	C. As Of The Critical Date, A POSA Would Not Have Had A Reasonable Expectation That 600 mg Of Mifepristone Could Be Safely And Effectively Used With A Strong CYP3A Inhibitor	23
	1. A POSA Would Not Have Used More Than 300 mg/day of Mifepristone With A Strong CYP3A Inhibitor.....	24
	(a) POSAs Followed The Instructions in the 2012 Korlym® Label Because of Safety Concerns	25
	(i) Pharmacokinetic Drug Interactions.....	25
	(ii) Pharmacodynamic Drug Interactions.....	26
	(iii) Difficulty in Identifying Adrenal Insufficiency ...	27
	(b) POSAs Followed The Teachings In The Art.....	27
	(c) Lee Taught Not To Co-Administer Mifepristone With Strong Or Moderate CYP3A Inhibitors.....	29
	2. Dr. Greenblatt’s Arguments Do Not Provide A Reasonable Expectation That 600 mg/day of Mifepristone Could Be Safely Administered With A Strong CYP3A Inhibitor	30

(a)	Dr. Greenblatt’s Argument That The Interaction Had “Not Been Studied”	30
(b)	Dr. Greenblatt’s Argument That The Label Permits “Doses Up To 1200 mg Per Day”	31
(c)	Dr. Greenblatt’s “Abundance of Caution” Argument	32
(d)	Dr. Greenblatt’s Argument That Lee “Explicitly Contemplated Amending the Labeling”	33
(e)	Dr. Greenblatt’s Argument That “Some Dose” Would Be Safe and Effective.....	35
(f)	Dr. Greenblatt’s “Routine Optimization” Argument	38
VII.	CONCLUSION.....	41

I, Laurence Katznelson, hereby declare and state as follows:

I submit this declaration on behalf of Corcept Therapeutics, Inc. (“Corcept”), the owner of U.S. Patent No. 10,195,214, (“the ’214 patent”) in connection with the Petition for Post-Grant Review filed by Teva Pharmaceuticals USA, Inc. (“Teva” or “Petitioner”).

I. INTRODUCTION

1. I have been asked to respond to certain opinions set forth in the Declaration of Dr. David J. Greenblatt, M.D. (“Greenblatt Declaration”) regarding the alleged invalidity of the ’214 patent that was submitted on behalf of Petitioner. I have also been asked to provide my own understanding of the state of the relevant art at the time of the invention claimed in the ’214 patent.

2. I am being compensated for my time at my usual rate of \$800 per hour. My compensation does not depend in any way on the substance of my testimony or the outcome of this or any other case.

3. I expressly reserve the right to supplement the opinions I express herein, as well as the bases for my opinions, in response to additional expert declarations submitted by Teva, or any additional discovery or information provided in this matter.

II. EXPERIENCE AND QUALIFICATIONS

4. I am a medical doctor specializing in the pathophysiology and treatment of pituitary diseases, including Cushing's syndrome. I am certified by the American Board of Internal Medicine in the field of Endocrinology, Diabetes and Metabolism. I have treated individuals with endogenous Cushing's syndrome for over 30 years.

5. I received my undergraduate degree (B.S., Genetics) from the University of California Berkley in 1981.

6. I received my medical degree from the University of California Los Angeles in 1985.

7. Following medical school, from 1986 to 1989, I completed a residency program in Internal Medicine at the Hospital of the University of Pennsylvania.

8. I then pursued a Fellowship in Endocrinology and Metabolism at Massachusetts General Hospital. While pursuing my Fellowship, in 1991, I became Board Certified in Endocrinology, Diabetes and Metabolism. I completed my Fellowship in 1992.

9. Between 1992 and 2004, I was an Instructor and then Assistant Professor of Medicine at Harvard Medical School, with a clinical and research focus on pituitary disorders.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.